Acurx announces new ibezapolstat data on anti-recurrence mechanisms in cdi at prominent international conference

Staten island, n.y. , july 1, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that using specimens from a phase 1 healthy volunteer trial and a novel analysis technique, beneficial changes potentially predictive of lower risk of cdi (clostridioides difficile infection) recurrence were associated with ibezapolstat compared to vancomycin.
ACXP Ratings Summary
ACXP Quant Ranking